JAK2 and acquired polycythemia vera: Their study employed a JAK2 V617F transgenic mouse model with an ET phenotype (72) and only 16 weeks of observation compared to our study, making their results not comparable with our JAK2 V617F transgenic mouse model, which recapitulated the natural history of PV, and required over 33 weeks of observation for full expression of the disease phenotype.